Abstract
Introduction

Endobronchial metastases from extrathoracic neoplasms are uncommon (1-3), and papillary serous carcinoma of the peritoneum (PSCP) is a rare primary peritoneal carcinoma that histologically resembles serous ovarian papillary carcinoma (4-6). Endobronchial metastasis is frequently associated with primary tumors of the kidney, colon/rectum, breast, and others (1-3, 7). To the best of our knowledge, there have been no previous reports of endobronchial metastasis from PSCP. A rare case of recurrent PSCP with endobronchial metastasis is reported.
Case Report
A 59-year-old woman was admitted to our hospital because of a 6- (Fig. 1a) . Chest computed tomography (CT) showed an endobronchial tumor of the left main 
p a c i t y a n d me d i a s t i n a l s h i f t . ( b ) CT s c a n s h o wi n g a n e n d ob r o n c h i a l t u mo r o f t h e l e f t ma i n t o t h e l o we r b r o n c h u s , a t e l e c t a s i s o f t h e l e f t l o we r l o b e , a n d me d i a s t i n a l s h i f t .
F i g u r e 2 . B r o n c h o s c o p i c p h o t o g r a p h s h o wi n g a n e n d o b r o n c h i a l p o l y p o f t h e l e f t ma i n b r o n c h u s .
to the lower bronchus, atelectasis of the left lower lobe, and mediastinal shift (Fig. 1b) . Bone scintigraphy revealed multiple bone metastases in the ribs.
On bronchoscopic examination, a large exophytic tumor was seen inside the left main bronchus, and it almost completely occluded the orifice of the left upper and lower lobes (Fig. 2) . A biopsy showed serous papillary adenocarcinoma (Fig. 3a) Fig. 3b, c, d (4, 5, (9) (10) (11) . The median survival time from the diagnosis of PSCP has been reported to be about 24 months (4, 6) . Although endobronchial metastasis from ovarian carcinoma has been reported (1, 12) , there are no reports of endobronchial metastasis from PSCP.
Discussion
Papillary serous carcinoma of the peritoneum (PSCP) is a rare malignant epithelial tumor that is histologically indistinguishable from serous ovarian papillary carcinoma, and it may be found predominantly in elderly postmenopausal women (4-6). PSCP is recognized as a primary tumor of the peritoneum that diffusely involves the peritoneal surface, while it spares or only superficially invades the ovaries (4, 5, 8). In the literature, about 10% of women diagnosed with epithelial ovarian carcinoma actually have PSCP, and the clinical features of PSCP closely resemble those of stage III-IV serous ovarian papillary carcinoma (4, 9, 10). The treatment strategies and the prognosis for PSCP are also similar to those of patients with stage III -IV ovarian serous papillary carcinoma
Since various definitions of endobronchial metastasis have been proposed, the reported frequencies of endobronchial metastasis vary, ranging from 2% to 50% of pulmonary metastases from extrathoracic neoplasms (1, 3, 7, 12, 13 (1) . In the present case, mediastinal and hilar lymphadenopathy were (1, 7, 14) . The recurrence interval from the diagnosis of the primary tumor to the diagnosis of EEM has been reported to be about 5 years, and the median survival time from the diagnosis of EEM has been reported to be about 10 months (1, 7, 14) . In the present case, the recurrence interval was 10 years, and the patient was treated with chemotherapy, which is regarded as standard treatment for ovarian carcinoma (4, 11) , and thoracic radiotherapy. She achieved a good response, and 32 months after the diagnosis of endobronchial metastasis (156 months after the diagnosis of PSCP), she was followed up as an outpatient. This is the first reported case of endobronchial metastasis from PSCP. Therefore, the present case reminds physicians to consider endobronchial metastasis from asymptomatic, extrathoracic neoplasms, and it may provide further insight into the clinical significance of PSCP.
F i g u r e 3 . A t r a n s b r o n c h i a l b i o p s y s p e c i me n f r o m t h e e n d o b r o n c h i a l t u mo r ( × 2 0 0 ) . ( a ) He ma t o xy l i n a n d E o s i n s t a i n i n g . ( b ) I mmu n o h i s t o c h e mi c a l s t a i n i n g wi t h a n t i -CA1 2 5 i s p o s i t i v e . ( c ) I mmu n oh i s t o c h e mi c a l s t a i n i n g wi t h a n t i -T T F -1 i s n e g a t i v e . ( d ) I mmu n o h i s t o c h e mi c a l s t a i n i n g wi t h a n t i -e st r o g e n r e c e p t o r i s p o s i t i v e .
